CLDX Celldex Therapeutics Inc: Accounting Value per Share

Graphic logo of Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX) is developing innovative mast cell immunotherapy, aiming for a sharp increase in profits via the drug Barzolvolimab. The market trend for the share price reflects the asset's dynamics, where the indicator stands at 9.19. The business model relies on external contractors for production and testing. Current capitalization depends entirely on the outcomes of monoclonal antibody research, as the company does not yet generate real sales.

Celldex Therapeutics Inc (CLDX): Share Book Value from 07/04/2022 to 10/27/2026

celldex.com - analytical breakdowns and key metrics (CLDX)

- price and consensus price forecast:
Stock Price Celldex|CLDX - Broker Consensus Forecast
- market capitalization data:
Market Valuation Celldex Therapeutics, Inc.|CLDX - Business Value
- book capitalization data:
Net Assets per Single Share Celldex Therapeutics|CLDX - Net Asset Value|Market Capitalization to Book Value Ratio celldex.com|CLDX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Celldex Therapeutics|CLDX - Long-Term Debt to Capital|Short-Term Debt to Equity Celldex Therapeutics, Inc.|CLDX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Celldex Therapeutics, Inc.
Fundamental company valuation:Celldex - CLDX
Manufactured products of Celldex Therapeutics, Inc.

For Celldex Therapeutics (CLDX), which is developing innovative immunotherapy and antibodies, the book value determines the actual value of the shareholder's stake. This metric is calculated as the difference between total assets and liabilities, divided by the number of shares. By analyzing the growth rate of the book value per share on GURU.Markets, an investor assesses the capitalization of resources for the development of barzolvolimab. Growth in this indicator confirms a strengthening financial foundation, which ensures a margin of safety when scaling the business.

Competitors of Celldex Therapeutics (CLDX)

Argenx (ARGX) - Book Value per Share|BioNTech Pharma (BNTX) - Equity per Share|Accounting Value per Share Abivax Corp|ADMA (admabiologics.com) - Equity per Share|Net Assets per Single Share Protagonist PTGX|Share Book Value Immunovant Inc|Kiniksa Pharmaceuticals Ltd (KNSA) - Book Value per Share|Accounting Value of a Share Grifols Biemat (GRFS)|Book Value per Share ADPT (Adaptive Biotechnologies)|auriniapharma.com - Book Value per Share|Net Assets per Single Share BioCryst Pharmaceuticals (BCRX)|VERA: Accounting Value of a Share|DNTH (Dianthus Pharma) - Net Assets per Single Share|Pharvaris Pharma (PHVS) - Accounting Value per Share|ABCL (AbCellera Biologics Inc) - Book Value per Share|Book Value per Share tourmalinebio.com (TRML)|Precigen (PGEN) - Accounting Value per Share|Accounting Value of a Share Pharming Group NV (PHAR)|Book Value per Share NKTR|Upstream Pharma - Net Assets per Share|ZBIO: Net Assets per Single Share|IMNM: Accounting Value per Share|GOSS (Gossamer Bio) - Net Assets per Single Share|Accounting Value per Share KalVista Pharma|SEPN (Septerna Corp) - Accounting Value per Share|Book Value per Share PVLA|Net Assets per Single Share Savara Inc. SVRA|Equity per Share rigel.com (RIGL)|ANAB: Book Value per Share|Net Asset Value per Share Astria Therapeutics Inc ATXS|ENGN: Book Value per Share|RAPT - Accounting Value per Share|Book Value per Share JBIO|ACRS (aclaristx.com) - Net Asset Value per Share|Net Assets per Single Share Kyverna Therapeutics, Inc.|Net Assets per Single Share TLSA|Net Assets per Single Share Cabaletta Bio, Inc (CABA)|Net Assets per Single Share Ventyx Biosciences, Inc (VTYX)|THTX - Book Value per Share|Equity per Share avalotx.com AVTX|ELDN (Eledon Pharmaceuticals, Inc.) - Book Value per Share|Agenus, Inc. (AGEN) - Net Asset Value per Share|Accounting Value per Share Climb Bio, Inc.|Equity per Share Zura Bio Ltd|ATYR - Accounting Value per Share|Accounting Value of a Share Adagene Corp (ADAG)|Accounting Value per Share ImageneBio Inc|Book Price of a Share shattucklabs.com (STTK)|Book Value per Share Equillium|Accounting Value of a Share Connect Biopharma Holdings CNTB|IMUX (Immunic Inc) - Book Value per Share|ATRA: Net Asset Value per Share|Net Assets per Single Share inflarx.de IFRX|X4 Pharmaceuticals Inc. (XFOR) - Accounting Value of a Share|ACET (Adicet Bio Inc.) - Book Value per Share|Book Value per Share CELU|INMB - Net Assets per Single Share|Share Book Value barinthusbio.com (BRNS)|KZR: Book Value per Share|SABS - Net Asset Value per Share|Akari Therapeutics plc - Accounting Value per Share|Enlivex Therapeutics (ENLV) - Book Value per Share|QTTB - Accounting Value per Share|geovax.com (GOVX) - Book Price of a Share|EDSA: Book Value per Share|Net Assets per Share iBio Inc|Book Value per Share CARM (Carisma Therapeutics)|Accounting Value per Share XTLB (XTL Bio)|Net Assets per Single Share BOLT|Net Assets per Share HCW Biologics, Inc. HCWB|APVO: Book Value per Share|AIM: Accounting Value per Share|aditxt.com (ADTX) - Net Assets per Single Share|GRI Bio Corporation (GRI) - Net Assets per Single Share|Book Value per Share XORTX Therapeutics Inc. (XRTX)|Equity per Share reshapelifesciences.com (HIND)|Accounting Value per Share Revelation Biosciences, Inc. REVB|Equity per Share INDP (Indaptus Therapeutics Inc)|Scinai (SCNI) - Net Assets per Single Share|Share Book Value CalciMedica Inc CALI|Book Value per Share Affimed Therapeutics (AFMD)|ALLK - Accounting Value of a Share|HOOK: Book Value per Share|IGMS (IGM Biosciences) - Book Value per Share|ITOS - Net Assets per Single Share|Accounting Value of a Share OCEA|Net Assets per Single Share TCBP (TC Biopharm)|Accounting Value per Share thirdharmonicbio.com (THRD)